Literature DB >> 18228527

Clinical significance of osteopontin expression in T1 and T2 tongue cancers.

Chih-Yen Chien1, Chih-Ying Su, Hui-Ching Chuang, Fu-Min Fang, Hsuan-Ying Huang, Ching-Mei Chen, Chang-Han Chen, Chao-Cheng Huang.   

Abstract

BACKGROUND: Osteopontin (OPN) is considered to be a tumor-related protein associated with tumor aggressiveness and metastasis.
METHODS: Immunohistochemistry was used to study the clinical significance of OPN expression in T1 and T2 tongue cancers.
RESULTS: Positive OPN expression significantly correlated with higher tumor classification (T) (p = .004), positive nodal classification (N) (p < .001), greater tumor thickness (p < .001), and presence of tumor necrosis (p = .016), respectively. The unfavorable cumulative 5-year disease-free survival rate significantly correlated with positive OPN expression (p < .001), T2 (p = .024), positive N (p < .001), greater tumor thickness (p = .023), and positive tumor necrosis (p = .003). However, taking CD105 into consideration, only CD105 expression was the independent prognostic factor for survival by Cox's regression analysis.
CONCLUSION: Overexpression of OPN in the tumors implicated a more aggressive tumor behavior and was an important factor for survival. In addition, there might be relationship between OPN and CD105 expressions in angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18228527     DOI: 10.1002/hed.20783

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  14 in total

1.  Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.

Authors:  Matthias Bache; Matthias Kappler; Henri Wichmann; Swetlana Rot; Antje Hahnel; Thomas Greither; Harun M Said; Matthias Kotzsch; Peter Würl; Helge Taubert; Dirk Vordermark
Journal:  BMC Cancer       Date:  2010-04-08       Impact factor: 4.430

Review 2.  OPN -Revisited.

Authors:  Vijayanirmala Subraman; Muthukumar Thiyagarajan; N Malathi; Sharada T Rajan
Journal:  J Clin Diagn Res       Date:  2015-06-01

3.  Expression of Osteopontin in Oral Squamous Cell Carcinoma and its Surgical Margins-An Immunohistochemical Study.

Authors:  Vijaya Nirmala Subramani; Malathi Narasimhan; Muthukumar Thiyagarajan; Balu David Munuswamy; Logeswari Jayamani
Journal:  J Clin Diagn Res       Date:  2015-11-01

4.  Osteopontin's colocalization with the adhesion molecule CEACAM5 in cytoplasm of carcinoma of tongue and its correlation with the invasion of that diease.

Authors:  Fan Zhang; Xu Jin Liu; Xun Qu; Zhen Sheng Hu; Yong Mei Yang; Ling Ma; Pei Liu; Ping Shi; Feng Cai Wei
Journal:  Cancer Cell Int       Date:  2012-06-27       Impact factor: 5.722

5.  Evaluating the efficacy of osteopontin expression as a prognostic marker in oral squamous cell carcinoma in the Indian subpopulation.

Authors:  Yashwant Ingale; Samapika Routray; Supriya M Kheur; Mohit Kheur; Neeta Mohanty
Journal:  J Oral Maxillofac Pathol       Date:  2014-09

6.  Prognosis of neutrophil-to-lymphocyte ratio in clinical early-stage tongue (cT1/T2N0) cancer.

Authors:  Ching-Nung Wu; Hui-Ching Chuang; Yu-Tsai Lin; Fu-Min Fang; Shau-Hsuan Li; Chih-Yen Chien
Journal:  Onco Targets Ther       Date:  2017-08-04       Impact factor: 4.147

7.  Biomolecular markers in cancer of the tongue.

Authors:  Daris Ferrari; Carla Codecà; Jessica Fiore; Laura Moneghini; Silvano Bosari; Paolo Foa
Journal:  J Oncol       Date:  2009-08-19       Impact factor: 4.375

Review 8.  Clinical implications of hypoxia biomarker expression in head and neck squamous cell carcinoma: a systematic review.

Authors:  Justin E Swartz; Ajit J Pothen; Inge Stegeman; Stefan M Willems; Wilko Grolman
Journal:  Cancer Med       Date:  2015-04-27       Impact factor: 4.452

9.  Osteopontin and oral carcinogenesis.

Authors:  Shailendra Kapoor
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

10.  Aurora-A signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior.

Authors:  Chih-Yen Chien; Hsin-Ting Tsai; Li-Jen Su; Hui-Ching Chuang; Li-Yen Shiu; Chao-Cheng Huang; Fu-Min Fang; Chun-Chieh Yu; Huei-Ting Su; Chang-Han Chen
Journal:  Oncotarget       Date:  2014-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.